Gadeta Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 38

Employees
  • Latest Deal Type

  • Early Stage VC

  • Investors

  • 4

Gadeta General Information

Description

Developer of innovative immunotherapies designed to treat cancer. The company's innovative immunotherapies are based on the discoveries regarding the role of yo T cell receptors (TCR's) in the broad recognition of hematological and solid tumor cells and their potential use for the treatment of advanced malignancies, enabling healthcare institutions and cancer patients to eradicate both hematological and solid tumors lowering the chances of cancer.

Contact Information

Website
www.gadeta.nl
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Yalelaan 62
  • 3584 CM Utrecht
  • Netherlands
+31 085 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gadeta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 19-Jul-2018 00.000 Completed Generating Revenue
2. Early Stage VC (Series A) 29-Mar-2016 00.000 00.000 Completed Startup
1. Seed Round Completed Startup
To view Gadeta’s complete valuation and funding history, request access »

Gadeta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative immunotherapies designed to treat cancer. The company's innovative immunotherapies are based on
Biotechnology
Utrecht, Netherlands
38 As of 2022
00.000
0000000000 0 00.000

00000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000

n voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gadeta Competitors (79)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pyxis Oncology Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 0 00000
000000-000 0000000 Venture Capital-Backed Palo Alto, CA 00 00000 0000000000 00000
You’re viewing 5 of 79 competitors. Get the full list »

Gadeta Patents

  • 22

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Gadeta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2013240658-A1 Combinatorial gamma 9 delta 2 t cell receptor chain exchange Granted 28-Mar-2012 00000000000
AU-2013240658-B2 Combinatorial gamma 9 delta 2 t cell receptor chain exchange Active 28-Mar-2012 00000000000
EP-2831109-B1 Combinatorial gamma 9 delta 2 t cell receptor chain exchange Active 28-Mar-2012 00000000000
US-20150050670-A1 Combinatorial gamma 9 delta 2 t cell receptor chain exchange Granted 28-Mar-2012 00000000000
AU-2017204731-B2 Combinatorial gamma 9 delta 2 t cell receptor chain exchange Active 28-Mar-2012 G01N33/5011
To view Gadeta’s complete patent history, request access »

Gadeta Executive Team (8)

Name Title Board Seat Contact Info
Marcel Zwaal Chief Executive Officer
Jurgen Kuball MD Co-Founder
Mark Throsby Ph.D Chief Scientific Officer & Chief Operating Officer
You’re viewing 3 of 8 executive team members. Get the full list »

Gadeta Board Members (7)

Name Representing Role Since
Giovanni Mariggi Ph.D Medicxi Board Member 000 0000
Mark De Boer Ph.D Medicxi Board Member 000 0000
Michèle Ollier MD Medicxi Board Member 000 0000
You’re viewing 3 of 7 board members. Get the full list »

Gadeta Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gadeta Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kite Pharma Corporation Majority 000 0000 000000 0
Baxalta Ventures Corporate Venture Capital Minority 000 0000 000000 0
Medicxi Venture Capital Minority 000 0000 000000 0
Utrecht Holdings Not-For-Profit Venture Capital Minority 000 0000 000000 0
To view Gadeta’s complete investors history, request access »

Ready to get started?

Request a free trial